Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Polynovo ( (AU:PNV) ) is now available.
PolyNovo has released a webcast recording of its FY25 results presentation for shareholders and interested parties who could not attend the live session. This announcement, authorized by the company’s secretary, includes updates from the CEO, financial results, chairman’s commentary, and a Q&A session, reflecting the company’s commitment to transparency and stakeholder engagement.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a disruptive medical technology company based in Melbourne, Australia, specializing in products that simplify the management of acute complex wounds. The company is known for its NovoSorb BTM, a dermal scaffold used for dermis regeneration, and has treated over 70,000 patients across 46 countries. PolyNovo is focused on growth through new products, indications, and market expansion.
Average Trading Volume: 2,086,632
Technical Sentiment Signal: Sell
Current Market Cap: A$759.9M
See more data about PNV stock on TipRanks’ Stock Analysis page.